ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer.

Kyte, J A; Andresen, N K; Russnes, H G; Fretland, S Ø; Falk, R S; Lingjærde, O C; Naume, B

Kyte, J A; Andresen, N K; Russnes, H G; Fretland, S Ø; Falk, R S; Lingjærde, O C; Naume, B.

Afiliação

Kyte JA; Department of Clinical Cancer Research, Oslo University Hospital, Oslo, Norway. jonky@ous-hf.no.
Andresen NK; Department of Cancer Immunology, Oslo University Hospital, Oslo, Norway. jonky@ous-hf.no.
Russnes HG; Department of Clinical Cancer Research, Oslo University Hospital, Oslo, Norway.
Fretland SØ; Department of Cancer Immunology, Oslo University Hospital, Oslo, Norway.
Falk RS; Department of Cancer Genetics, Oslo University Hospital, Oslo, Norway.
Lingjærde OC; Department of Pathology, Oslo University Hospital, Oslo, Norway.
Naume B; Department of Clinical Cancer Research, Oslo University Hospital, Oslo, Norway.

J Transl Med ; 18(1): 269, 2020 07 03.

Article em En | MEDLINE | ID: mdl-32620163

Assuntos

Neoplasias da Mama; Nivolumabe; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico; Neoplasias da Mama/tratamento farmacológico; Hormônios; Humanos; Ipilimumab/uso terapêutico; Nivolumabe/uso terapêutico

Palavras-chave

Anthracycline; Breast cancer; CTLA4; Checkpoint inhibitor; Cyclophosphamide; Hormone receptor positive; Immunogenic cell death; Immunotherapy; PD-1

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Nivolumabe Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google